



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kocken et al.

Serial No.: 10/615,615

Filed: July 8, 2003

For: EFFICIENT EXPRESSION OF
PLASMODIUM APICAL MEMBRANE
ANTIGEN 1 IN YEAST CELLS

Confirmation No.: 8276

Examiner: R. Akhavan

Group Art Unit: 1636

Attorney Docket No.: 2183-6041US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV669815117US

Date of Deposit with USPS: July 10, 2006

Person making Deposit: Wendy Neff

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Other Documents

TAYLOR et al., "Effect of Falciparum Malaria Infection on the in Vitro Mitogen Responses of Spleen and Peripheral Blood Lymphocytes from Owl Monkeys," Am. J. Trop. Med. Hyg., 1978, pp. 738-742 , Vol. 27, No. 4.

KOCKEN et al., "High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium Falciparum Apical Membrane Antigen 1 and Induction of Antibodies that Inhibit Erythrocyte Invasion," Infection and Immunity, Aug. 2002, pp. 4471-4476, Vol. 70, No. 8.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.:	2183-6042US
Serial No.:	10/623,472
Filing Date:	7/18/2003
Title:	CLONING AND EXPRESSION OF A NEW MCP RECEPTOR IN GLIAL CELLS

Serial No. 10/615,615

This Supplemental Information Disclosure Statement is filed concurrently with an RCE in the above-identified application, and therefore no additional fee is due.

Respectfully submitted,



Krista Weber Powell
Registration No. 47,867
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: July 10, 2006
KWP/sfc:lmh/bv

Enclosures: Form PTO/SB/08
Cited Nonpatent Documents

Document in ProLaw



Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/615,615
Filing Date	July 8, 2003
First Named Inventor	Kocken et al.
Group Art Unit	1636
Examiner Name	R. Akhavan
Attorney Docket Number	2183-60411 US (ME/P54200US00)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TAYLOR et al., "Effect of Falciparum Malaria Infection on the in Vitro Mitogen Responses of Spleen and Peripheral Blood Lymphocytes from Owl Monkeys," Am. J. Trop. Med. Hyg., 1978, pp. 738-742, Vol. 27, No. 4.	
		KOCKEN et al., "High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium Falciparum Apical Membrane Antigen 1 and Induction of Antibodies that Inhibit Erythrocyte Invasion," Infection and Immunity, Aug. 2002, pp. 4471-4476, Vol. 70, No. 8.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.